Home|Contact us|Site map
Our partners & alliances
Our partners
Strategic alliances
 
 

Strategic alliances

 

Oncodesign’s objective is to have a major role in improving anticancer treatment. The final mission of the company is to develop its own therapies and, before to complete this mission, Oncodesign is able to provide clinician with technological innovations. That’s why Oncodesign has designed its 3-years R&D program in two major themes:

The first theme is to improve the development of new tools and techniques that will facilitate and accelerate the passage of new anticancer compounds from the preclinical stage to the clinic. This theme is composed of Axis I & Axis II described below.
The second theme is to discover innovative targets involved in oncology. This theme is represented by Axis III.


Axis I: Development and characterization of in vivo cancer models

The major objective of this R&D project is to setup new experimental models of xenografted mice and rats based on the use of two regulatory sources of human primary tumor tissues. These new models will also be characterized by proteomic and genomic analysis or by target expression analysis using immunohistochemistry in tissue arrays.

Axis II: Research of new imaging biomarkers of activity

This R&D project aims to provide solutions to problems that are encountered during clinical trials when using novel anticancer targeted therapies: clinicians need to have access to relevant and early biomarkers of activity of new compounds and to determine the active biological dose of a novel therapy. The use of imaging techniques that are directly usable in the clinic, such as MRI/MRS, allow for better elucidation of the mechanism of action and potential of activity of novel therapies.

Axis III: Innovative target identification


Oncodesign is involved in the FP6 with European academic laboratories in the Plurigen project. This axis is based on various collaborations that aim to identify innovative targets implicated in proliferation or apoptosis. When a target has been identified, Oncodesign is in charge of its validation using its original target validation platform.
 
 
 
Back
Top
About us  /  Services & Facilities  /  Our partners & alliances  /  Media  /  Careers
Terms of use
Copyright © 2007. Oncodesign® Biotechnology. All rights reserved